Pancreatic Neoplasm Clinical Trial
Official title:
Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass
EUS-guided FNA has been proved to be a safe and useful method for tissue sampling of
gastrointestinal track lesions and other organ lesions including mediastinal and
intra-abdominal lymph nodes, pancreas and hepatobiliary tree. The usefulness of EUS-FNA
depends on several factors. For example, experience of the endosonographers, adequate
sampling, sample preparing, accurate interpretation by the cytopathologist and on-site
cytopathology interpretation. However, in many hospitals, no cytopathologist can be present
during EUS-FNA. Therefore, determining appropriate methods to obtain and prepare EUS-guided
FNA are important to make correct a diagnosis without on-site cytopathologist.
Suction with a self-retracting 10-mL syringe will likely bring in more cellularity but also
more blood. Some endosonographers use no suction, others use constant suction. Usually
specimen is expelled from a needle with pushing the stylet into the needle. But use of the
stylet during EUS-FNA is difficult and time consuming process. Injecting air was not
recommended, because of spraying out uncontrollably, increasing risk of air artifact and
specimen clotting. However, there is no further study which one is the appropriate, suction
or no suction and pushing the stylet or injecting air until now.
The hypothesis and aim of the prospective randomized controlled trials are as follows:
First hypothesis: There was no difference in the adequacy, cellularity, bloodiness,
contamination, air artifact in specimen obtained by each methods, suction or no suction and
pushing the stylet or injecting air.
Aim #1 : To compare the adequacy, cellularity, bloodiness, contamination, air artifact in
specimen obtained by each methods, suction or no suction and pushing the stylet or injecting
air.
Second hypothesis: There was no difference in sensitivity, specificity, diagnostic accuracy,
positive predictive value, negative predictive value and statistical agreement in specimen
obtained by each methods, suction or no suction and pushing the stylet or injecting air.
Aim #2 : To compare the sensitivity, specificity, diagnostic accuracy, positive predictive
value, negative predictive value and statistical agreement in specimen obtained by each
methods, suction or no suction and pushing the stylet or injecting air.
On-site cytopathology interpretation during EUS-FNA has a significant clinical impact by
increasing the diagnostic yield of the FNA. However, many hospitals do not have provision
for on- site diagnosis of EUS FNA specimen. Therefore, optimal specimen obtainment and
preparation of EUS FNA are is important to accurate diagnosis. EUS FNA is performed with or
without self-retracting 10-mL syringe according to endosonographer's preference. In general,
if there is too little cellularity on immediate cytologic evaluation, then use more suction,
and, conversely, if the samples are too bloody, then use less suction. However, it is hard
to determine the quality of specimen without on-site cytopathology interpretation. The
actual way material is expressed from the needle may influence yield. Injecting air to
express the material is problematic, because the material may spray out uncontrollably, risk
of air artifact and specimen clotting may increase . A more controlled method is to pushing
the stylet and slowly advance it to the needle tip. But use of the stylet during EUS-FNA is
not only difficult and time consuming process but also increasing the risk of accidental
needle stick injury. However, there is no firm evidence which one is the appropriate,
suction or no suction and pushing the stylet or injecting air. If there was no significant
difference between each methods, appropriate methods of obtaining and preparing aspirates
undergoing EUS-FNA is no suction and injecting air and EUS FNA may perform more easier and
shorter.
In this prospective randomized controlled trial, patients with peripancreatic mass for
EUS-FNA will be included. One patient will be underwent at least four puncture during
EUS-FNA. The sequence of EUS-FNA with first four methods will be selected by using a
randomization scheme obtained from a sealed envelope : (1) negative pressure suction with 10
mL syringe and pushing the stylet; (2) negative pressure suction with 10 mL syringe and
injecting air; (3) without negative pressure suction and pushing the stylet; (4) without
negative pressure suction and injecting air. EUS FNA will be performed by two experienced
endosonographers. All specimens will be read by same experienced pathologist blinded to
methods.
The investigators will compare between the four groups in terms of adequacy, cellularity,
bloodiness, contamination, air artifact. The sensitivity, specificity, diagnostic accuracy,
positive predictive value, negative predictive value and statistical agreement for the
different methods will be calculated.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00958841 -
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Terminated |
NCT02602067 -
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
|
Phase 1 | |
Recruiting |
NCT06411795 -
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
|
Phase 2 | |
Completed |
NCT03622229 -
EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle
|
N/A | |
Recruiting |
NCT06400472 -
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02791503 -
CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy
|
N/A | |
Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
Completed |
NCT05745415 -
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
|
||
Completed |
NCT03322592 -
EUS-FNB With ROSE Vs. EUS-FNB Without ROSE
|
N/A | |
Recruiting |
NCT05083247 -
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT00436423 -
A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02900950 -
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
|
N/A | |
Completed |
NCT00711191 -
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
|
Phase 1 | |
Completed |
NCT00222898 -
Cancer Detection in Pancreatic Cysts
|
N/A | |
Completed |
NCT00034281 -
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
|
Phase 1 | |
Completed |
NCT00005926 -
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
|
Phase 2 | |
Recruiting |
NCT04164017 -
Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions
|
N/A | |
Recruiting |
NCT05687123 -
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
|
Phase 1 |